Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Novel combination therapy for AML based on CD44-mediated co-delivery of Daunorubicin, Cytarabine, and CD47 siRNA

Li, Qinzhe (2023) Novel combination therapy for AML based on CD44-mediated co-delivery of Daunorubicin, Cytarabine, and CD47 siRNA. Master's Thesis, University of Pittsburgh. (Unpublished)

[img] PDF
Restricted to University of Pittsburgh users only until 4 May 2025.

Download (842kB) | Request a Copy


The conventional “7+3” treatment regimen of daunorubicin and cytarabine has been a mainstay treatment for acute myeloid leukemia (AML) patients. However, one major limitation is the rapid elimination of the free drugs, resulting in the requirement of continuous drug infusion. A novel liposomal formulation of daunorubicin and cytarabine, CPX-351, was approved by FDA in 2017, which improved the survival outcome among elder patients, but the system lacks selective targeting of AML cells. CD47 is highly expressed in AML cells and serves as a “don’t eat me” signal to halt the phagocytosis upon binding with the SINPα receptors on macrophages. Antibodies that target CD47 can facilitate the phagocytosis of AML cells by macrophages but are associated with several adverse effects in animal studies including acute anemia. Here, a novel nanocarrier (PMBOP) is evaluated for the co-delivery of daunorubicin, cytarabine, and CD47 siRNA. With the ability to target CD44 on AML cells, we seek to improve the therapeutic outcome of AML treatment by increasing the bioavailability and reducing off-target effects.


Social Networking:
Share |


Item Type: University of Pittsburgh ETD
Status: Unpublished
CreatorsEmailPitt UsernameORCID
Li, Qinzheqil94@pitt.eduqil94
ETD Committee:
TitleMemberEmail AddressPitt UsernameORCID
Committee ChairLi,
Committee MemberMa,
Committee MemberBrixius,
Date: 4 May 2023
Date Type: Publication
Defense Date: 11 April 2023
Approval Date: 4 May 2023
Submission Date: 18 April 2023
Access Restriction: 2 year -- Restrict access to University of Pittsburgh for a period of 2 years.
Number of Pages: 35
Institution: University of Pittsburgh
Schools and Programs: School of Pharmacy > Pharmaceutical Sciences
Degree: MS - Master of Science
Thesis Type: Master's Thesis
Refereed: Yes
Uncontrolled Keywords: Leukemia
Date Deposited: 04 May 2023 16:12
Last Modified: 04 May 2023 16:12


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item